Which medications should a 46‑year‑old woman with a prior myocardial infarction be on for secondary prevention?

Post-MI Medications for a 46-Year-Old Woman

A 46-year-old woman with a history of myocardial infarction should be on aspirin, a high-intensity statin, a beta-blocker, and an ACE inhibitor (or ARB if intolerant), with consideration for aldosterone blockade if she has left ventricular dysfunction or heart failure. 1

Core Medication Regimen

Antiplatelet Therapy

• Aspirin 75-162 mg daily indefinitely is mandatory unless contraindicated 1
• If aspirin is absolutely contraindicated, substitute with clopidogrel 75 mg daily 1
• If she received a stent during her MI, dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor) for at least 12 months is required 1
  • Options include clopidogrel 75 mg, prasugrel 10 mg, or ticagrelor 90 mg twice daily 1
  • After stent placement, use higher-dose aspirin 325 mg daily for 1 month (bare metal) to 6 months (drug-eluting stent), then reduce to 75-81 mg 1

Lipid-Lowering Therapy

• High-intensity statin therapy should be initiated and continued indefinitely 1
• High-intensity statins include atorvastatin 40-80 mg or rosuvastatin 20-40 mg daily 1
• The goal is at least a 50% reduction in LDL-C, not simply achieving an LDL target 1
• Only 27-35% of post-MI patients receive appropriate high-intensity statins despite clear evidence of benefit 1

Beta-Blockers

• Beta-blockers should be started and continued indefinitely after MI 1
• For patients with left ventricular systolic dysfunction or heart failure, use one of three proven agents: bisoprolol, carvedilol, or extended-release metoprolol succinate 1
• Beta-blockers reduce mortality by 23% in post-MI patients and are particularly beneficial in those with heart failure, systolic cardiomyopathy, or ventricular arrhythmias 1
• Guidelines recommend at least 3 years of treatment for uncomplicated MI, though many patients continue indefinitely 1

ACE Inhibitors or ARBs

• ACE inhibitors should be started and continued indefinitely in all post-MI patients, particularly those with left ventricular ejection fraction <40%, heart failure, hypertension, or diabetes 1
• For patients without these specific indications, ACE inhibitors are still recommended as they provide cardiovascular protection 1
• ARBs are indicated for patients intolerant of ACE inhibitors who have heart failure or left ventricular ejection fraction ≤40% 1
• Valsartan was shown to be as effective as captopril in high-risk post-MI patients 1

Aldosterone Blockade

• Use aldosterone blockade (spironolactone or eplerenone) in post-MI patients with left ventricular ejection fraction <40% and either diabetes or heart failure, provided they don't have significant renal dysfunction (creatinine ≤2.5 mg/dL in men, ≤2.0 mg/dL in women) or hyperkalemia 1
• This should be added to therapeutic doses of ACE inhibitor and beta-blocker 1

Additional Considerations

Blood Pressure Management

• Target blood pressure <130/80 mm Hg if she has hypertension 1
• If ventricular dysfunction is present, consider lowering to <120/80 mm Hg 1
• Thiazide diuretics can be added if needed for blood pressure control 1

Diabetes Management (if applicable)

• Metformin is the preferred first-line agent 1
• Target HbA1c ≤7% if achievable without significant hypoglycemia 1

Influenza Vaccination

• Annual influenza vaccination is recommended for all patients with cardiovascular disease 1

Common Pitfalls to Avoid

Underdosing statins: Only 27-35% of post-MI patients receive high-intensity statins at discharge 1. Ensure atorvastatin 40-80 mg or rosuvastatin 20-40 mg is prescribed, not lower-intensity regimens.

Premature discontinuation: Discontinuation rates range from 12-14% at 1 year to 36-51% at 12 years across medication classes 2. Emphasize the lifelong nature of these medications.

Omitting ACE inhibitors in "low-risk" patients: Even patients without left ventricular dysfunction benefit from ACE inhibitors 1. The only exception is truly low-risk patients with normal ejection fraction and well-controlled risk factors after revascularization 1.

Using non-evidence-based beta-blockers: In patients with systolic dysfunction, only bisoprolol, carvedilol, or extended-release metoprolol succinate have proven mortality benefit 1.

Forgetting aldosterone blockade: This is frequently overlooked in eligible patients with reduced ejection fraction and diabetes or heart failure 1.